SEC Tracker
Get the app
ERNA · XBRL financial data

Ernexa Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ERNA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Revenue5117*47474871*——————
Cost of revenue12066*6195(60)0*—0———0
Gross profit(69)(49)*(14)(48)5471*——————
General and administrative3,9794,506*4,3153,8963,3811,540*1,4211,3659581,418*1,6311,312
Total operating expenses5,4365,716*5,7734,8832,8062,698*2,7302,5011,9932,094*5,5904,104
Operating income (loss)(5,505)(5,765)*(5,787)(4,931)(2,259)(2,697)*(2,730)(2,501)(1,993)(2,094)*(5,590)(4,104)
Interest expense—63*1008001,7003,200*80016*0*0*——
Other income (expense)(1)(53)*———year only(135)(123)(6)479*—(1)
Income tax expense (benefit)(8)(4)*431211*836(62)*(40)0*
Net income (loss)(5,591)(6,153)*(6,647)(5,529)(26,604)(5,759)*(8,202)(3,139)(1,240)(1,502)*(5,506)(4,009)
Earnings per share, basic USD per share(1.03)(1.14)*(1.23)(1.02)(4.92)—(0.15)(0.61)(0.15)—(6.95)(3.40)
Earnings per share, diluted USD per share(1.03)(1.14)*(1.23)(1.02)(4.92)—(0.15)(0.61)(0.15)—(6.95)(3.40)
Weighted average shares, basic thousands of shares5,4105,412*5,4105,4105,410—53,3615,1798,226—7921,183
Weighted average shares, diluted thousands of shares5,4105,412*5,4105,4105,410—53,3615,1798,226—7921,183
  • † Share count changed about 1/8 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/25 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ERNA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Cash and cash equivalents4,5517,5755,1162,5864,2641,7291,9184,3153,0471,8849,1775,028
Prepaid and other current assets7041,599697769279186137323179404724783
Total current assets7,0319,5996,1643,5834,7302,3522,2114,7923,3793,1339,9965,894
Property and equipment, net17349371065410585675092948882
Right-of-use asset34,86032,78136,52435,990719670619581541453349314
Goodwill2,0442,0442,0442,0442,0442,0442,0442,0442,0442,044——
Total assets52,24849,13249,65746,4867,7185,2695,0597,5846,1725,83410,5436,315
Accounts payable1,4641,0672,0632,1932,1931,7211,2751,3199581,1251,3001,375
Accrued liabilities5,0191,8931,8682,3891,1661,0071,3549388598981,4811,016
Total current liabilities9,6266,5737,7689,6009,9522,93810,4382,6512,1443,1133,4572,932
Lease liability, non-current34,99832,85436,56536,044534477419376346277226182
Total liabilities48,68646,89953,06955,01253,1113,56811,0093,1402,6023,4333,6843,115
Accumulated deficit(180,820)(186,981)(193,628)(199,165)(225,769)(231,536)(239,738)(242,885)(244,126)(245,636)(251,142)(255,159)
Total stockholders' equity3,5622,233(3,412)(8,526)(45,393)1,701(5,950)4,4443,5702,4016,8593,200
Total liabilities and equity52,24849,13249,65746,4867,7185,2695,0597,5846,1725,83410,5436,315
Common shares outstanding (cover page) thousands of shares5,4105,4105,4105,41151,37552,24562,3647,6717,84929,1541,1661,632
  • † Share count changed about 1/8 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/25 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ERNA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Net income (loss)(5,591)(6,153)*(6,647)(5,529)(26,604)(5,759)*(8,202)(3,139)(1,240)(1,502)*(5,506)(4,009)
Stock-based compensation174*165*282423*405*410*502368*293*333*309320*
Depreciation and amortization20*22*3944*37*19*1817*17*13*89*
Net cash from operating activities(5,826)*(4,661)*(3,747)(2,259)*(6,285)*(3,545)*(2,065)(2,532)*(1,272)*(1,148)*(2,264)(4,152)*
Purchases of property and equipment0*19*101249*19*0*———15*23*
Net cash from investing activities0*(19)*(97)(249)*(19)*0*———(15)*(2)(3)*
Proceeds from issuing common stock0*0*———year only——0*0*10,480—
Proceeds from issuing equity———————7,201—0*——
Net cash from financing activities8,540*7,704*1,385(22)*3,887*1,010*2,2544,929*26*0*9,5596*
  • † Share count changed about 1/8 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/25 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Ernexa Therapeutics5,028not reported(4,152)*1.6M1.2 quarters 10-QJun 30, 2026
Marker Therapeutics11,331not reported(3,716)*16.7M3.0 quarters 10-QJun 30, 2026
Charlie's Holdings527not reported(383)*280.6M1.4 quarters 10-QJun 30, 2026
Cognition Therapeutics34,012not reported(3,053)*95.1M11.1 quarters 10-QJun 30, 2026
IGC Pharma331265(1,350)*103.4M0.3 quarters 10-QJun 30, 2026
Lipocine4,979190(3,028)*8.2M7.7 quarters 10-QJun 30, 2026
Relmada Therapeutics11,334not reported(9,606)*106.7M22.7 quarters 10-QJun 30, 2026
CEL-SCI6,527not reported(4,031)*17.6M1.6 quarters 10-QJun 30, 2026
CalciMedica18,617not reported(4,620)*34.1M4.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.